Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.20
NYSE:PRGO's Cash-to-Debt is ranked lower than
87% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. NYSE:PRGO: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:PRGO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.23 Max: 18.02
Current: 0.2
0
18.02
Equity-to-Asset 0.53
NYSE:PRGO's Equity-to-Asset is ranked lower than
64% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:PRGO: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:PRGO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.56 Max: 0.75
Current: 0.53
0.35
0.75
Debt-to-Equity 0.54
NYSE:PRGO's Debt-to-Equity is ranked lower than
66% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. NYSE:PRGO: 0.54 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:PRGO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.4 Max: 1.23
Current: 0.54
0
1.23
Debt-to-EBITDA 2.90
NYSE:PRGO's Debt-to-EBITDA is ranked lower than
67% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. NYSE:PRGO: 2.90 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:PRGO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.5  Med: 3.12 Max: 5.73
Current: 2.9
1.5
5.73
Interest Coverage 2.33
NYSE:PRGO's Interest Coverage is ranked lower than
85% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 132.39 vs. NYSE:PRGO: 2.33 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:PRGO' s Interest Coverage Range Over the Past 10 Years
Min: 2.32  Med: 9.59 Max: 13.16
Current: 2.33
2.32
13.16
Piotroski F-Score: 9
Altman Z-Score: 1.78
Beneish M-Score: -2.68
WACC vs ROIC
5.35%
4.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.29
NYSE:PRGO's Operating Margin % is ranked higher than
61% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. NYSE:PRGO: 14.29 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:PRGO' s Operating Margin % Range Over the Past 10 Years
Min: 11.12  Med: 16.07 Max: 19.52
Current: 14.29
11.12
19.52
Net Margin % 2.42
NYSE:PRGO's Net Margin % is ranked lower than
62% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NYSE:PRGO: 2.42 )
Ranked among companies with meaningful Net Margin % only.
NYSE:PRGO' s Net Margin % Range Over the Past 10 Years
Min: -75.99  Med: 7.32 Max: 12.66
Current: 2.42
-75.99
12.66
ROE % 1.97
NYSE:PRGO's ROE % is ranked lower than
63% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. NYSE:PRGO: 1.97 )
Ranked among companies with meaningful ROE % only.
NYSE:PRGO' s ROE % Range Over the Past 10 Years
Min: -48.18  Med: 15.81 Max: 25.88
Current: 1.97
-48.18
25.88
ROA % 0.95
NYSE:PRGO's ROA % is ranked lower than
62% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. NYSE:PRGO: 0.95 )
Ranked among companies with meaningful ROA % only.
NYSE:PRGO' s ROA % Range Over the Past 10 Years
Min: -23.98  Med: 5.89 Max: 11.14
Current: 0.95
-23.98
11.14
ROC (Joel Greenblatt) % 41.98
NYSE:PRGO's ROC (Joel Greenblatt) % is ranked higher than
80% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. NYSE:PRGO: 41.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:PRGO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.08  Med: 40.82 Max: 53.43
Current: 41.98
30.08
53.43
3-Year Revenue Growth Rate 0.80
NYSE:PRGO's 3-Year Revenue Growth Rate is ranked lower than
67% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NYSE:PRGO: 0.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:PRGO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.5  Med: 7.5 Max: 16.8
Current: 0.8
-5.5
16.8
3-Year EBITDA Growth Rate 4.00
NYSE:PRGO's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.90 vs. NYSE:PRGO: 4.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:PRGO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.1 Max: 45.5
Current: 4
0
45.5
3-Year EPS without NRI Growth Rate -25.20
NYSE:PRGO's 3-Year EPS without NRI Growth Rate is ranked lower than
88% of the 657 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. NYSE:PRGO: -25.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:PRGO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 210.7
Current: -25.2
0
210.7
GuruFocus has detected 4 Warning Signs with Perrigo Co PLC NYSE:PRGO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:PRGO's 30-Y Financials

Financials (Next Earnings Date: 2018-05-23)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

PRGO Guru Trades in Q1 2017

Jeremy Grantham 165,592 sh (New)
David Einhorn 1,700,000 sh (New)
Paul Tudor Jones 13,281 sh (+181.14%)
Murray Stahl 11,262 sh (+12.14%)
First Eagle Investment 4,800 sh (unchged)
Jeremy Grantham 400,000 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons Sold Out
George Soros Sold Out
First Pacific Advisors Sold Out
Manning & Napier Advisors, Inc 2,420,836 sh (-5.85%)
Ken Fisher 481,172 sh (-6.52%)
Ruane Cunniff 617,478 sh (-53.05%)
» More
Q2 2017

PRGO Guru Trades in Q2 2017

First Eagle Investment 34,200 sh (New)
Joel Greenblatt 330,376 sh (New)
Jim Simons 362,508 sh (New)
David Einhorn 2,527,000 sh (+48.65%)
Manning & Napier Advisors, Inc 2,586,068 sh (+6.83%)
First Eagle Investment 4,800 sh (unchged)
Jeremy Grantham 400,000 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Ruane Cunniff Sold Out
Murray Stahl 10,957 sh (-2.71%)
Ken Fisher 465,952 sh (-3.16%)
Jeremy Grantham 45,199 sh (-72.70%)
Paul Tudor Jones 3,624 sh (-72.71%)
» More
Q3 2017

PRGO Guru Trades in Q3 2017

Steven Cohen 150,100 sh (New)
David Einhorn 2,901,032 sh (+14.80%)
Robert Bruce 9,926 sh (unchged)
Jeremy Grantham Sold Out
First Eagle Investment Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 10,607 sh (-3.19%)
Ken Fisher 447,270 sh (-4.01%)
Manning & Napier Advisors, Inc 2,240,413 sh (-13.37%)
Joel Greenblatt 135,767 sh (-58.91%)
Jim Simons 115,208 sh (-68.22%)
» More
Q4 2017

PRGO Guru Trades in Q4 2017

Pioneer Investments 36,791 sh (New)
Paul Tudor Jones 2,398 sh (New)
Jim Simons 448,408 sh (+289.22%)
Robert Bruce Sold Out
Steven Cohen Sold Out
Ken Fisher 439,981 sh (-1.63%)
Murray Stahl 10,401 sh (-1.94%)
David Einhorn 2,836,632 sh (-2.22%)
Joel Greenblatt 6,249 sh (-95.40%)
» More
» Details

Insider Trades

Latest Guru Trades with PRGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Add 15.63%0.01%$79.57 - $95.15 $ 82.73-5%508,749
David Einhorn 2017-12-31 Reduce -2.22%0.09%$80.7 - $88.58 $ 82.73-4%2,836,632
Ken Fisher 2017-12-31 Reduce -1.63%$80.7 - $88.58 $ 82.73-4%439,981
Joel Greenblatt 2017-12-31 Reduce -95.40%0.16%$80.7 - $88.58 $ 82.73-4%6,249
Robert Bruce 2017-12-31 Sold Out 0.21%$80.7 - $88.58 $ 82.73-4%0
David Einhorn 2017-09-30 Add 14.80%0.5%$66.37 - $89.01 $ 82.736%2,901,032
Ken Fisher 2017-09-30 Reduce -4.01%$66.37 - $89.01 $ 82.736%447,270
Joel Greenblatt 2017-09-30 Reduce -58.91%0.21%$66.37 - $89.01 $ 82.736%135,767
First Eagle Investment 2017-09-30 Sold Out 0.01%$66.37 - $89.01 $ 82.736%0
David Einhorn 2017-06-30 Add 48.65%1.01%$66.14 - $76.5 $ 82.7316%2,527,000
Ken Fisher 2017-06-30 Reduce -3.16%$66.14 - $76.5 $ 82.7316%465,952
Joel Greenblatt 2017-06-30 New Buy0.35%$66.14 - $76.5 $ 82.7316%330,376
First Eagle Investment 2017-06-30 New Buy0.01%$66.14 - $76.5 $ 82.7316%34,200
Ruane Cunniff 2017-06-30 Sold Out 0.39%$66.14 - $76.5 $ 82.7316%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:TSE:4508, OCSE:LUN, XPAR:IPN, SZSE:000963, JSE:APN, XSWX:VIFN, HKSE:03320, SZSE:300122, TSE:4581, SHSE:600085, TSE:4507, SHSE:600332, SHSE:600535, BSP:HYPE3, SZSE:002001, XTER:SAZ, TSE:4506, SZSE:000423, TSE:4530, SZSE:000538 » details
Traded in other countries:PIG.Germany, PRGO.Israel,
Headquarter Location:Ireland
Perrigo Co PLC is a healthcare company providing branded OTC products throughout Europe and the USA. It sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China.

Perrigo is the largest store-brand over-the-counter pharmaceutical and infant formula manufacturer. The company operates four segments: consumer health care, branded consumer healthcare, prescription pharmaceuticals, and active pharmaceutical ingredients. In the United States, Perrigo sells about 2,100 products with 9,000 stock-keeping units. Following the acquisition of Omega Pharma, approximately 25% of the company's revenue comes from outside the U.S.

Guru Investment Theses on Perrigo Co PLC

David Einhorn Comments on Perrigo - May 17, 2017

Perrigo (NYSE:PRGO) is the largest manufacturer of private label over -the-counter (OTC) pharmaceutical products for U.S. retailers and pharmacy chains. Over the past decade the company acquired other business lines, including a portfolio of European OTC brands (Omega), a generics pharmaceutical business, and a royalty stream on a large multiple sclerosis drug that has since been divested. In November 2015, shareholders rejected a hostile takeover offer from Mylan worth $175 per share after the then-CEO laid out ambitious standalone earnings targets. Unfortunately for shareholders, these targets proved far too optimistic and the CEO ultimately departed. After several large guidance cuts, we believe the new management team has now set achievable earnings forecasts. Omega’s business suffered from large restructuring expenses last year that should not recur and has additional margin upside as it streamlines its product portfolio. The company also has a dominant market position in its core U.S. OTC business and should continue to grow profits in this segment. We believe the U.S. OTC business and Omega have profit and growth characteristics similar to consumer products businesses, which trade at healthy multiples due to the stability of their cash flows. We purchased PRGO at an average price of $68.81 per share or 11x our estimate of 2019 earnings. PRGO shares ended the quarter at $66.39.





  • From Einhorn's first-quarter 2017 shareholder commentary.


Check out David Einhorn latest stock trades

Jerome Dodson Comments on Perrigo - Jan 25, 2017

The Fund’s weakest performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock plummeted 42.5%, from $144.70 to $83.23, cutting 103 basis points from the Fund’s return. The shares sank in April after longtime CEO Joe Papa resigned to become the CEO of Valeant Pharmaceuticals. The stock continued to move lower throughout the year as the company cut its earnings guidance three times, from nearly $10 per share to just $7. The business underperformed due to declining prescription generic drug prices and soft growth from Omega, Perrigo’s European business. We sold our position during the year due to our concerns that the prescription generic pricing environment would get worse and that it would take longer than expected to fix Omega.



From the Parnassus Fund fourth quarter 2016 commentary.



Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Perrigo - Nov 01, 2016

We sold Perrigo (NYSE:PRGO), a producer of store-brand generic drugs, due to our concerns that the generic pricing environment would get worse and that it would take longer than expected to improve the company’s European platform. Additionally, we sold credit card issuer American Express, because we believe its moat is narrowing. Intense competition for the company’s affluent cardholders is pushing up rewards costs and marketing expenses, thereby lowering the company’s return on capital.

From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third-quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

Keeley Funds Comment on Perrigo Co. - Aug 03, 2016

Perrigo Co. (NYSE:PRGO) was the Fund’s leading detractor this quarter. The stock price dropped over 22% and cost the Fund 62 basis points in performance. The company focuses on the production of over-the-counter consumer goods and specialty pharmaceutical products. The stock price dropped after the former CEO departed to join Valeant Pharmaceuticals and the Board of Directors named a new CEO. The new CEO promptly reduced guidance, causing an increase in skepticism about management’s ability to integrate a recent European acquisition.



From Keeley Funds' All Cap Value Fund second quarter commentary.



Check out John Keeley latest stock trades

Jerome Dodson Comments on Perrigo - Jul 26, 2016

Four companies each contributed 20 basis points or more to the Fund’s return this quarter, but six subtracted 20 basis points or more from the return. Our worst performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock sank 29.1% from $127.93 to $90.67, cutting 69 basis points from the Fund’s return. Shares plummeted in April after longtime CEO Joe Papa resigned to become the CEO at Valeant Pharmaceuticals, and Perrigo lowered its 2016 guidance for the second time this year. The business has underperformed due to declining generic drug prices and weak growth from Omega, Perrigo’s European business. While we think John Hendrickson, Perrigo’s new CEO, is the right person for the job given his strong operational background, we’re continuing to monitor the drug pricing environment.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

David Rolfe Comments on Perrigo - Jul 13, 2016

During the quarter, a surprising decline in Perrigo (NYSE:PRGO)’s normally staid generic prescription (Rx) business had the Company reduce full-year guidance by almost 15% in a late-April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of disconcerting data points, we decided it prudent to liquidate our Perrigo stake.

We think that, at its core, Perrigo’s U.S. private label over-the-counter (OTC) business is intrinsically attractive, with nearly 70% market share and long-tailed revenue streams similar to that of a consumer staple. Private-label OTC was about 50% of the Company’s calendar 2015 revenue, and nearly 40% of consolidated operating profitability.

Another third of Perrigo’s profits was derived from their generic Rx business which we believed, until recently, was relatively defensible. We had seen that Perrigo’s strategy in generic Rx was to target drugs that had small addressable markets (often less than $50 million per year sales), but a good probability of eventually becoming approved for OTC. We hypothesized that Perrigo’s rivals were slow to copy Perrigo generic drugs either because the addressable market was not big enough, and/or because margins on OTC are dramatically lower than Rx, particularly for sub-scale OTC manufacturers. (Private-label OTC manufacturing, marketing, and distribution support capabilities are substantially different from prescription). In other words, we saw Perrigo’s substantial scale in private-label OTC as enabling the Company to realize unique economics in other parts of their business, namely generic Rx. Therefore, it was surprising to us when the Company cut its own guidance for this unit by double-digits and then offered little in the way of an outlook, despite having provided a steady outlook just a few months ago.

Further, Perrigo’s relatively new BCH platform continued to underperform. The company expended almost $4.5 billion in shareholder capital to acquire BCH’s core asset, Omega Pharmaceutical, in early 2015. We think this business will be ineffective as a growth platform, despite management’s previous optimism. The Company has commented that the highly entrepreneurial culture of Omega has made it difficult to scale this business through further bolt-on acquisitions. The scaling of acquisitions has been a key component of Perrigo’s long-term growth strategy, so we would not be surprised if there are more examples of unrealized value- destruction embedded in the Omega acquisition.

Finally, Mr. Joe Papa, now former CEO of Perrigo, abruptly exited the Company in late April.
 Mr. Papa’s exit came after having spent countless hours and money, with the Board of Directors’ encouragement and unanimous approval, fending off Mylan’s hostile bid on the basis of the following: Perrigo’s stock being undervalued, Mylan’s poor corporate governance record, and the risk of dis-synergies. We now find shares trading at about half the supposedly undervalued bid price; Mr. Papa’s departure to run a company with one of the worst corporate governance track records around, dis-synergies from the Omega acquisition; and a materially weakened generic Rx franchise. Importantly, we think that execution missteps are expected over the long term and therefore manageable (if only because we can handicap those hiccups by building in a valuation cushion). However, we do not invest in Companies that are not forthcoming with their investor base. We question the credibility of Perrigo’s remaining management team, as well as the Board of Directors. In our experience, fortunately, this has been thankfully rare.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Perrigo - Jul 13, 2016

Perrigo (NYSE:PRGO) detracted –1.04% from the composite's absolute performance. A surprising decline in Perrigo’s normally staid generic prescription (Rx) business had the company reduce full-year guidance by almost 15% in a late April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of data points, we decided it prudent to liquidate our Perrigo stake.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

Top Ranked Articles about Perrigo Co PLC

Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn
Impax Launches a Generic Version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%)
Weekly CEO Buys Highlight Details the CEO buys this past week from the following companies: American Assets Trust, Continental Resources, OPKO Health, Forum Energy Technologies and Perrigo Co.
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. Read more...
The Bruce Fund Bets on Botox and Steel Robert Bruce piles up on Allergan and manufacturer of steel wire products
Robert Bruce (Trades, Portfolio)’s Chicago-based investment fund, Bruce & Co., boosted its stake in Botox maker Allergan as the company begins multimillion-dollar cost cuts, including an elimination of 1,000 jobs. Read more...
Perrigo to Present at Upcoming Investor Conferences
Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Mucinex® DM Maximum Strength Extended Release Tablets
Stocks Fall in Premarket Trade J.C. Penney crashes on fourth quarter results
U.S. markets are set to open low on Friday after President Donald Trump said trade wars are good, and the entire world is worried about this kind of comment. Read more...
Perrigo Files Form 10-K With SEC; Will Host Fourth Quarter And Calendar Year 2017 Financial Results Conference Call On March 2, 2018
Perrigo Company plc Reports Select Preliminary Unaudited Calendar Year 2017 Financial Results
Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%

Ratios

vs
industry
vs
history
PE Ratio 99.68
PRGO's PE Ratio is ranked lower than
91% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.44 vs. PRGO: 99.68 )
Ranked among companies with meaningful PE Ratio only.
PRGO' s PE Ratio Range Over the Past 10 Years
Min: 13.34  Med: 25.99 Max: 2122.57
Current: 99.68
13.34
2122.57
Forward PE Ratio 15.67
PRGO's Forward PE Ratio is ranked higher than
65% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. PRGO: 15.67 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 99.68
PRGO's PE Ratio without NRI is ranked lower than
91% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.44 vs. PRGO: 99.68 )
Ranked among companies with meaningful PE Ratio without NRI only.
PRGO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.89  Med: 26.08 Max: 2122.57
Current: 99.68
12.89
2122.57
PB Ratio 1.89
PRGO's PB Ratio is ranked higher than
69% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. PRGO: 1.89 )
Ranked among companies with meaningful PB Ratio only.
PRGO' s PB Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.03 Max: 5.96
Current: 1.89
1.27
5.96
PS Ratio 2.38
PRGO's PS Ratio is ranked higher than
57% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. PRGO: 2.38 )
Ranked among companies with meaningful PS Ratio only.
PRGO' s PS Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.63 Max: 6.68
Current: 2.38
0.89
6.68
Price-to-Free-Cash-Flow 19.31
PRGO's Price-to-Free-Cash-Flow is ranked higher than
61% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.03 vs. PRGO: 19.31 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PRGO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.07  Med: 27.15 Max: 84.98
Current: 19.31
11.07
84.98
Price-to-Operating-Cash-Flow 16.88
PRGO's Price-to-Operating-Cash-Flow is ranked higher than
53% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.21 vs. PRGO: 16.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PRGO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.52  Med: 19.48 Max: 40.27
Current: 16.88
8.52
40.27
EV-to-EBIT 20.28
PRGO's EV-to-EBIT is ranked lower than
62% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. PRGO: 20.28 )
Ranked among companies with meaningful EV-to-EBIT only.
PRGO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10  Med: 20.2 Max: 48.8
Current: 20.28
10
48.8
EV-to-EBITDA 12.44
PRGO's EV-to-EBITDA is ranked higher than
60% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. PRGO: 12.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.9  Med: 15.4 Max: 31.3
Current: 12.44
7.9
31.3
EV-to-Revenue 2.90
PRGO's EV-to-Revenue is ranked higher than
54% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. PRGO: 2.90 )
Ranked among companies with meaningful EV-to-Revenue only.
PRGO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 3.3 Max: 7.9
Current: 2.9
1.2
7.9
Current Ratio 1.96
PRGO's Current Ratio is ranked lower than
62% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. PRGO: 1.96 )
Ranked among companies with meaningful Current Ratio only.
PRGO' s Current Ratio Range Over the Past 10 Years
Min: 1.52  Med: 2.36 Max: 2.98
Current: 1.96
1.52
2.98
Quick Ratio 1.40
PRGO's Quick Ratio is ranked lower than
64% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. PRGO: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
PRGO' s Quick Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.22 Max: 2.87
Current: 1.4
0.79
2.87
Days Inventory 99.46
PRGO's Days Inventory is ranked higher than
60% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. PRGO: 99.46 )
Ranked among companies with meaningful Days Inventory only.
PRGO' s Days Inventory Range Over the Past 10 Years
Min: 92.5  Med: 99.4 Max: 110.74
Current: 99.46
92.5
110.74
Days Sales Outstanding 83.44
PRGO's Days Sales Outstanding is ranked lower than
57% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. PRGO: 83.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.9  Med: 68.69 Max: 104.43
Current: 83.44
57.9
104.43
Days Payable 55.39
PRGO's Days Payable is ranked lower than
65% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. PRGO: 55.39 )
Ranked among companies with meaningful Days Payable only.
PRGO' s Days Payable Range Over the Past 10 Years
Min: 53.32  Med: 62.91 Max: 100.23
Current: 55.39
53.32
100.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.82
PRGO's Dividend Yield % is ranked lower than
74% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. PRGO: 0.82 )
Ranked among companies with meaningful Dividend Yield % only.
PRGO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.22  Med: 0.4 Max: 1.09
Current: 0.82
0.22
1.09
Dividend Payout Ratio 0.76
PRGO's Dividend Payout Ratio is ranked higher than
75% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.31 vs. PRGO: 0.76 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PRGO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.13 Max: 0.76
Current: 0.76
0.07
0.76
3-Year Dividend Growth Rate 18.00
PRGO's 3-Year Dividend Growth Rate is ranked higher than
72% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. PRGO: 18.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PRGO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8 Max: 49.8
Current: 18
0
49.8
Forward Dividend Yield % 0.92
PRGO's Forward Dividend Yield % is ranked lower than
73% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. PRGO: 0.92 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.75
PRGO's 5-Year Yield-on-Cost % is ranked lower than
54% of the 889 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. PRGO: 1.75 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PRGO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.47  Med: 0.85 Max: 2.33
Current: 1.75
0.47
2.33
3-Year Average Share Buyback Ratio -1.70
PRGO's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. PRGO: -1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRGO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: 0.2 Max: 1.9
Current: -1.7
-16.1
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.18
PRGO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. PRGO: 1.18 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PRGO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1  Med: 1.64 Max: 2.32
Current: 1.18
1
2.32
Price-to-Median-PS-Value 0.91
PRGO's Price-to-Median-PS-Value is ranked higher than
63% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. PRGO: 0.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRGO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 0.59 Max: 2.32
Current: 0.91
0.24
2.32
Earnings Yield (Greenblatt) % 4.94
PRGO's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. PRGO: 4.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRGO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.1  Med: 4.9 Max: 10
Current: 4.94
2.1
10
Forward Rate of Return (Yacktman) % 1.93
PRGO's Forward Rate of Return (Yacktman) % is ranked lower than
82% of the 414 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.53 vs. PRGO: 1.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PRGO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.1  Med: 10.6 Max: 22.9
Current: 1.93
1.1
22.9

More Statistics

Revenue (TTM) (Mil) $4,946.30
EPS (TTM) $ 0.83
Beta0.79
Volatility20.32%
52-Week Range $63.68 - 95.93
Shares Outstanding (Mil)140.87

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 5,016 5,145 5,233
EBIT (Mil $) 947 1,171 1,264
EBITDA (Mil $) 1,233 1,307 1,192
EPS ($) 5.36 5.82 6.07
EPS without NRI ($) 5.36 5.82 6.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.67%
Dividends per Share ($) 0.42 0.58 0.86

Piotroski F-Score Details

Piotroski F-Score: 99
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}